Trial Profile
A Phase 2 Open-label Multi-centre Study to Evaluate the Efficacy and Safety of Oxabact to Reduce Plasma Oxalate in Subjects With Primary Hyperoxaluria Who Are on Dialysis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2022
Price :
$35
*
At a glance
- Drugs Lyophilised Oxalobacter formigenes (Primary)
- Indications Primary hyperoxaluria
- Focus Therapeutic Use
- Sponsors OxThera
- 18 Aug 2020 Status has been changed to active, no longer recruiting.
- 18 Aug 2020 Results published in the Nephrology Dialysis Transplantation
- 06 Apr 2020 According to an OxThera media release, positive results from this study were presented at the 2020 American Society of Nephrology.